A phase I/II trial of OXB 102 for treatment of Parkinson's disease
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Parkinson's disease gene therapy (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2017 According to an Oxford BioMedica media release, the company has been working on appropriate regulatory approvals for this planned three cohort Phase I/II study to be conducted in Cambridge and London, UK and Paris, France.
- 18 Mar 2015 The title is not official. Trial focus assumed.
- 18 Mar 2015 New trial record